Reporting by The Hindu.
Read More at The Hindu
INDIA EDITION
--- VIEWS
U.S. FDA approves first-line use of Boehringer Ingelheim's lung cancer drug
TLN
Editorial Team
Boehringer's Hernexeos was one of the 18 drugs selected so far for the FDA Commissioner's National Priority Voucher Program that allows speedy process and cuts the review time to one to two months from the typical 10 to 12 months
Share this story
Reader Reactions
Reader Comments
No comments yet.
